Dr Sulaiman Al Habib Medical Group (4013) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Dr Sulaiman Al Habib Medical Group stock SAR 109, price SAR 222, upside -50.6%, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range 144.31 SAR – 320.47 SAR · fair‑value band 45.44 SAR – 145.47 SAR · the 221.50 SAR price screens above the 109.45 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Dr Sulaiman Al Habib Medical in your weekly email
Every Wednesday you see whether Dr Sulaiman Al Habib Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dr. Sulaiman Al Habib Medical Services Group Company, together with its subsidiaries, provides private health and support services in the Kingdom of Saudi Arabia. It operates through three segments: Hospitals/Healthcare Facilities, Pharmacies, and Other Solutions Sector.
Show moreShow less
The company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities.
It also provides home medical care; specialized medical laboratories; information technology and systems; facility maintenance; telemedicine; revenue cycle management; and medical equipment maintenance services, as well as engages in real estate activities.
The company was founded in 1993 and is based in Riyadh, the Kingdom of Saudi Arabia.
Stock analysis
Dr Sulaiman Al Habib Medical Group (4013) currently trades at 221.50 SAR, while our model-based Fair Value estimate is 109.45 SAR, 50.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 164.61 SAR per share, and 1 of the 24 models we run sit above the 221.50 SAR price.
Bear case: the Asset-Based group reads lowest at 15.13 SAR, and 23 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 45.44 SAR (bear) to 145.47 SAR (bull), the price of 221.50 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Dr Sulaiman Al Habib Medical Group reported revenue of 13.7B SAR in FY2025 versus 7.3B SAR in FY2021, a compound +17.3%/yr. Reported net income was 2.4B SAR in FY2025, compounding +14.9%/yr from FY2021.
Key figures
Market cap 77.5B SAR (≈ $20.7B) Large · P/E ratio 31.9 · P/S ratio 5.35 · EPS (TTM) 6.94 SAR · Dividend yield 2.2% · Net margin 16.6% · Return on equity 30.1% · Return on assets (EBIT) 12.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −51%, 4013 screens richer than that median.
Fair Value models
Bear45.44 SARFair Value 109.45 SARBull145.47 SAR
Price 221.50 SAR · Upside -50.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.72 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
Start year 2020 (pandemic). Over 10 years: +10.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+20.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.9%
Dividend (yield on the price)2.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.9% vs 7.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 19%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +8.4% a year for the forecasts.
Compare Dr Sulaiman Al Habib Medical Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 242 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside−50.9% · Bottom 25%
Profitability
Return on equity (12 months)30.1% · Top 25%
Return on assets10.4% · Top 25%
Net margin (12 months)16.6% · Top 25%
Operating margin (12 months)19.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)18.4% · Top 25%
Dividend yield (12 months)2.2% · Above median
Balance sheet
Debt / equity1.11× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)31.9× · Pricier than median
P/B9.88× · Priciest 25%
P/S (12 months)5.35× · Priciest 25%
EV/EBITDA24.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 37
FUTURE (revenue growth)92· sector 32
PAST (return on equity)100· sector 33
HEALTH (low debt)45· sector 90
DIVIDEND (yield)44· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dr Sulaiman Al Habib Medical Group Fair Value". https://www.fairvalue-calculator.com/stock/4013
Frequently asked questions
Is Dr Sulaiman Al Habib Medical Group (4013) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 109.45 SAR versus a price of 221.50 SAR, about −51% upside (overvalued).
What is the fair value of 4013?
Our model-based fair value for Dr Sulaiman Al Habib Medical Group is 109.45 SAR (as of Oct 28, 2026), built from audited fundamentals. The current price: 221.50 SAR.
What is the quality score of 4013?
Dr Sulaiman Al Habib Medical Group has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dr Sulaiman Al Habib Medical Group (4013)?
Our model-based price target is the fair value of 109.45 SAR (as of Oct 28, 2026) from 24 valuation models. Cautious scenario 45.44 SAR, optimistic scenario 145.47 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Dr Sulaiman Al Habib Medical Group stock forecast for 2026?
Our models put fair value at 109.45 SAR, about −51% upside versus a price of 221.50 SAR (overvalued). Cautious scenario 45.44 SAR, optimistic scenario 145.47 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Dr Sulaiman Al Habib Medical Group (4013)?
Dr Sulaiman Al Habib Medical Group reported trailing-twelve-month revenue of about 14.6B SAR (latest available figure, as of Oct 28, 2026).
Does Dr Sulaiman Al Habib Medical Group pay a dividend?
Dr Sulaiman Al Habib Medical Group currently shows a dividend yield of 2.19% relative to its recent price (as of Oct 28, 2026).
What growth is priced into Dr Sulaiman Al Habib Medical Group (4013)?
For today's price to be fair in a discounted-cash-flow model, Dr Sulaiman Al Habib Medical Group would have to grow free cash flow by more than 80 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.5 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of 4013 use?
Our models discount Dr Sulaiman Al Habib Medical Group at 8.6 %: a base by market capitalisation (large), damped by beta 0.03, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dr Sulaiman Al Habib Medical Group that is more than 80 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Dr Sulaiman Al Habib Medical Group (4013) delivered so far?
Over the past 5 years revenue at Dr Sulaiman Al Habib Medical Group grew +18.5 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dr Sulaiman Al Habib Medical Group (4013) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Dr Sulaiman Al Habib Medical Group (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dr Sulaiman Al Habib Medical Group (4013)?
The free-cash-flow yield on the price is 0.13 %: that much free cash flow Dr Sulaiman Al Habib Medical Group produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dr Sulaiman Al Habib Medical Group (4013)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dr Sulaiman Al Habib Medical Group it is 109.45 SAR per share (as of Oct 28, 2026), against a price of 221.50 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Dr Sulaiman Al Habib Medical Group stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 4013 trades above its calculated fair value: price 221.50 SAR, fair value 109.45 SAR, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4013?
No. The price is what the market pays today (221.50 SAR); the fair value is what the company's own numbers justify (109.45 SAR). For Dr Sulaiman Al Habib Medical Group the two are 112.05 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Dr Sulaiman Al Habib Medical Group worth?
The market values Dr Sulaiman Al Habib Medical Group at about 77.5B SAR (market capitalisation, as of Oct 28, 2026). Per share that is 221.50 SAR; our models calculate a fair value of 109.45 SAR per share.
What do the bullish and bearish scenarios say about 4013?
Our models span a range for Dr Sulaiman Al Habib Medical Group: cautious scenario 45.44 SAR, base 109.45 SAR, optimistic 145.47 SAR per share (as of Oct 28, 2026, price 221.50 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4013?
Dr Sulaiman Al Habib Medical Group trades at a price-to-earnings ratio of 31.9 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 109.45 SAR is built from several models across several years. Other multiples: P/B 9.9, P/S 5.3, EV/EBITDA 24.9.
How solid is the balance sheet of Dr Sulaiman Al Habib Medical Group (4013)?
Balance-sheet figures for Dr Sulaiman Al Habib Medical Group (as of Oct 28, 2026): return on equity 30.1%, debt of 1.11 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 4013 from its 52-week high?
Dr Sulaiman Al Habib Medical Group trades at 221.50 SAR, about 17% below its 52-week high of 268.00 SAR and 6% above the low of 209.80 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 109.45 SAR is for.
Which stocks are comparable to Dr Sulaiman Al Habib Medical Group?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Encompass Health Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dr Sulaiman Al Habib Medical Group stock attractive at the current price?
The data as of Oct 28, 2026: price 221.50 SAR, calculated fair value 109.45 SAR (−51%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4013 calculated?
We run Dr Sulaiman Al Habib Medical Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 109.45 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Dr Sulaiman Al Habib Medical Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dr Sulaiman Al Habib Medical Group (4013)?
The closing price on Oct 29, 2026 was 221.50 SAR. Our model-based fair value is 109.45 SAR, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dr Sulaiman Al Habib Medical Group right now?
The price sits above even our optimistic bull case (145.47 SAR). The favourable scenario is already priced in. The model range is unusually wide (45.44 SAR to 145.47 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Dr Sulaiman Al Habib Medical Group (4013) come from?
Earnings per share at Dr Sulaiman Al Habib Medical Group grew +8.0 % a year from 2015 to 2025. Broken into its drivers: revenue per share +10.3 %, EBIT margin −1.2 %, tax rate +0.4 %, residual (interest, one-offs) −1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Dr Sulaiman Al Habib Medical Group
How large is the market capitalisation of Dr Sulaiman Al Habib Medical Group (4013)?
The market capitalisation of Dr Sulaiman Al Habib Medical Group is 77.5B SAR (≈ $20.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dr Sulaiman Al Habib Medical Group (4013)?
The price-to-sales ratio of Dr Sulaiman Al Habib Medical Group is 5.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dr Sulaiman Al Habib Medical Group (4013)?
Earnings per share at Dr Sulaiman Al Habib Medical Group are 6.94 SAR (price ÷ EPS = P/E 31.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dr Sulaiman Al Habib Medical Group (4013)?
The dividend yield of Dr Sulaiman Al Habib Medical Group is 2.2% (payout 70.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dr Sulaiman Al Habib Medical Group (4013)?
The net margin of Dr Sulaiman Al Habib Medical Group is 16.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dr Sulaiman Al Habib Medical Group (4013)?
The return on equity (ROE) of Dr Sulaiman Al Habib Medical Group is 30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dr Sulaiman Al Habib Medical Group (4013)?
On an EBIT basis the return on assets of Dr Sulaiman Al Habib Medical Group is 12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dr Sulaiman Al Habib Medical Group (4013)?
The operating margin of Dr Sulaiman Al Habib Medical Group is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dr Sulaiman Al Habib Medical Group (4013)?
Revenue at Dr Sulaiman Al Habib Medical Group is growing +18.4% versus a year earlier (3y avg +18.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dr Sulaiman Al Habib Medical Group (4013)?
Earnings per share at Dr Sulaiman Al Habib Medical Group are growing +12.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Dr Sulaiman Al Habib Medical Group (4013) carry?
The net debt of Dr Sulaiman Al Habib Medical Group is 7.0B SAR (fiscal year 2025, ≈ 69.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Dr Sulaiman Al Habib Medical Group in the live analysis
One click puts Dr Sulaiman Al Habib Medical Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 28, 2026